Newton Biocapital
Venture capitalBrussels · Seed–Series A · 16 people tracked
Investment thesis
Newton Biocapital invests in life sciences innovation across Europe and Japan, leveraging strong ties to both regions' ecosystems to unlock cross-border opportunities and optimal exits through connections with local and international investors and pharma. The fund targets promising solutions for chronic health conditions with an aim to reduce patient and societal burdens. Drawing on the team's scientific and medical expertise plus a network of experts, the firm identifies opportunities across a range of technologies and disease areas, and participates actively as board members, supporting portfolio companies with their preclinical and clinical program selection to create value for patients, society, local ecosystems, and investors.
Source: firm website, verified Aug 3, 2026.
Team · 16 people
from the firm's website & curated & public directories
What they invest in
from 15 of 16 portfolio companiesBiotech ×13Healthtech ×10Medical Devices ×8Deep Tech ×5Digital Health ×4AI & Machine Learning ×3Longevity ×1
HQs:Belgium×5Japan×4European Union×1France×1
Investments · 16 tracked
founders shown can be your intro pathAbolerIS Pharma develops therapeutic approaches that regulate the immune system by inducing immune tolerance while preserving useful immune responses, targeting inflammatory, autoimmune, and degenerative diseases.
BiotechHealthtech
Ignacio Anegon(Co-founder, Senior Consultant & SAB Member)Carole Guillonneau(Co-founder & Head of Research)inFrançois-Xavier Hubert(Co-founder, Past President & Board Member)
Co-investorsCriteria Bio VenturesSound BioventuresSambrinvestWallonie Entreprendre
DeuterOncology is a clinical-stage biotech developing DO-2, a deuterated, brain-penetrant MET kinase and RAS pathway inhibitor for cancer patients, currently in a phase 1 clinical study.
BiotechHealthtechMedical DevicesLiege, BE
Dr Timothy PereraTimothy Perera(Founder & CEO)in
Neuvasq Biotechnologies is a biotech spin-off from the Université libre de Bruxelles developing therapies that target the Gpr124/Reck signaling complex to repair the blood-brain and blood-CNS barriers in neurological and cerebrovascular disorders.
BiotechDeep TechHealthtechMedical Devices
Benoit Vanhollebeke(Scientific Founder)inDenis Bedoret(Executive Director)in
Co-investorsSambrinvestWallonie Entreprendre
Sequana Medical develops the alfapump system and DSR therapy for treating fluid overload in patients with conditions such as liver disease and heart failure.
BiotechHealthtechMedical DevicesGhent, BE
Co-investorsBlackRockEQT Life SciencesKreos CapitalRosetta Capital Ltd.VI PartnersBootstrap Europe+2 more
PRISM BioLab is a biotechnology company that develops PepMetics, a proprietary drug discovery platform of small molecules designed to mimic α-helix or β-turn peptides, aiming to target proteins previously considered "undruggable." The company maintains a screening library of over 20,000 compounds and partners with pharmaceutical firms on drug discovery programs.
AI & Machine LearningBiotechDeep TechTokyo, JP
Co-investorsDBJ CapitalEisai Innovation, Inc.
Acticor Biotech is a clinical-stage biopharmaceutical company developing treatments for stroke and other cardiovascular emergencies, focused on the acute phase of these conditions.
BiotechDigital Health
Co-investorsKarista
AdipoPharma is a French biotech company developing PATAS, a first-in-class stapled peptide insulin sensitizer that targets adipocytes to treat insulin resistance, type 2 diabetes, and associated comorbidities.
BiotechLongevityMedical Devices
Vincent Marion(Founder, President & CEO)Catherine Perot(Chief Financial Officer)Michael J. Fare(Chief Operating Officer)Tarekegn G. Hiwot(Chief Medical Officer)
Co-investorsGood Growth Capital
Co-investorsFund+
Dim3 provides medical device software and hardware for clinical nutrition management, helping doctors, dietitians, and nurses detect malnutrition risks, plan personalized nutrition interventions, and track patient outcomes in real-time across healthcare settings.
Digital HealthHealthtechMedical Devices
EPICS Therapeutics develops RNA epigenetics-based cancer treatments, focusing on METTL3 inhibitors for cancers including non-small cell lung cancer, pancreatic cancer, ovarian cancer, and colorectal cancer where existing therapies are insufficient.
BiotechDigital HealthMedical Devices
Co-investorsFund+
Perseus Proteomics (PPMX) is a Japanese biotech company that uses proprietary antibody technology to develop new antibody-based drugs.
BiotechDeep TechHealthtech
Co-investorsDBJ CapitalKyoto University Innovation CapitalNippon Venture CapitalSMBC Venture Capital
Santero is a Belgium-based biotech company developing antibacterial drugs, including an RSH inhibitor programme targeting Pseudomonas aeruginosa and multidrug-resistant pathogens.
AI & Machine LearningBiotechDeep TechHealthtechBrussels, BE
Abel Garcia-Pino(Co-founder & Scientific Advisor)inCédric Govaerts(Co-founder & Scientific Advisor)inMark Beards(Chief Executive Officer)inEmilie Racine(COO & Head of Chemistry)inCuong Vuong(Chief Scientific Officer)inValérie Gallien(Chief of Staff)in
Synergia Medical develops optoelectronic implantable medical devices, including its NAO.VNS vagus nerve stimulation system, which is undergoing First-In-Human clinical evaluation through the AURORA study.
Deep TechHealthtechMedical DevicesBrussels, BE
Charles Nolet(CEO)Vincent De Rudder(VP QARA)Gijs Klarenbeek(VP of Clinical)Dan Scherrer(COO)Dimitri Crelot(CFO)
Tensegrity is a pharmaceutical company focused on drug discovery and development, aiming to reduce R&D bottlenecks and bring new drugs to market.
BiotechHealthtech
EditForce develops proprietary PPR gene-editing technology that can modify both DNA and RNA, with applications in medicine, agriculture, and chemical industries.
AI & Machine LearningBiotech
Co-investorsGlobal BrainKDDI Open Innovation Fund
J-Pharma is a drug development company focused on SLC transporter-targeted therapies, with its lead LAT1 inhibitor nanvuranlat (JPH203) in a global Phase 3 trial for biliary tract cancer and other candidates addressing cancer, autoimmune, and rare diseases.
BiotechDigital HealthHealthtechMedical DevicesTokyo, JP
𠮷武 益広(代表取締役社長 (Representative Director & President))藤本 裕(取締役CFO)山本 寛(取締役CBO)
Co-investorsF-Prime CapitalOita Venture CapitalOSAKA University Venture CapitalSeibu Shinkin CapitalUntroD Capital
Portfolio news
latest coverage across their companiesPerseus Proteomics · tipranks.com · Aug 13, 2026
Frequently asked questions
- How many investments has Newton Biocapital made?
- Newton Biocapital has 16 tracked investments.
- What stage does Newton Biocapital invest at?
- Newton Biocapital invests at the Seed, Series A stages.
- What sectors does Newton Biocapital focus on?
- Newton Biocapital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Newton Biocapital located?
- Newton Biocapital is headquartered in Brussels, BE.
- Does Newton Biocapital lead rounds?
- Yes, Newton Biocapital leads investment rounds.
- Who does Newton Biocapital co-invest with?
- Newton Biocapital most often shares deals with DBJ Capital, Fund+, F-Prime Capital, among 19 tracked co-investors.
Images
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.